Takeda Clears Last U.S. Court Hurdle To Save Actos Patent
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said the U.S. Supreme Court has ruled in its favor in a patent case involving its Actos (pioglitazone hydrochloride) diabetes drug. Alphapharm had appealed to the high court to overturn an Appeals Court decision in favor of Takeda, but the Supreme Court declined to review the case, leaving the appeals court's decision final. The court outcome makes it unlikely U.S. FDA would approve Alphapharm's generic version of the drug. The Takeda patent on the drug expires in 2011. (Click here for more